Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

New Technology Reduces Drug Development Costs

By BiotechDaily International staff writers
Posted on 04 Feb 2013
New technology based on cytochrome P450s (CYPs) proteins will speed up and reduce the cost of the development of new drugs and medicines.

The CYP super-family is a large and diverse group of enzymes that catalyze the oxidation of organic substances. The substrates of CYP enzymes include metabolic intermediates such as lipids and steroidal hormones, as well as xenobiotic substances such as drugs and other toxic chemicals. CYPs are the major enzymes involved in drug metabolism and bioactivation, accounting for about 75% of the total number of different metabolic reactions. The proteins are commercially available for use by companies involved in the discovery of new drugs, but are problematic as they must be transported and stored at temperatures as low as minus 80 degrees Celsius.

Researchers at De Montfort University (DMU; Leicester, United Kingdom) therefore developed a method that allows for CYPs to be shipped and handled at room temperature, eliminating the need for a cold chain, reducing costs, and making CYPs use in testing new drugs much quicker and easier. For the venture, DMU joined forces with life sciences commercialization company Ithaka Life Sciences (Ithaka, Cambridge, United Kingdom) to jointly establish a new company, which will be called CYP Design Limited (CDL, Cambridge, United Kingdom).

“The development of new drugs can be very time-consuming and costly. It can take up to 14 years from the initial idea and cost hundreds of millions of pounds. Thousands of potential new drugs are tested initially for every one successfully brought to market,” said Professor Bob Chaudhuri, PhD, who developed the new technology. “My group's development is designed to provide the proteins that are needed for this work in a cost effective and convenient format.”

“The technology that Professor Chaudhuri has been developing can have a significant impact on the timescales and costs involved in the early stages of drug discovery,” said Bill Primrose, PhD, CEO of CDL. “CYPs are currently transported on dry ice, at around minus 80 degrees Celsius, and are stored as cold as possible in the customer's laboratory until they are needed. His new technology eliminates the need for a cold chain, making it easier to manufacture and ship the proteins, and making them much more convenient for the customer to use.”

CYP-mediated transformations of drug candidates are of crucial importance in the pharmaceutical industry, with multiple roles. Oxidation by CYPs can lead to toxic products, but, on the other hand, local activation of anticancer drugs leads to lethal intracellular toxins at the site of the tumor. The metabolic clearance of most drugs depends on CYPs, and they have been implicated in a large number of drug interactions. Since drug interactions can result in fatalities, drug candidates with CYPs must be taken into account if the expensive and time-consuming development of active compounds with hidden toxic effects is to be avoided.

Related Links:

De Montfort University
Ithaka Life Sciences




Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.